[Four departments issued a document: Strengthening the safe and rational deployment and use of innovative drugs] On November 10th, the National Health Commission, the National Medical Insurance Administration, the State Administration of Traditional Chinese Medicine, and the State Administration of Disease Control and Prevention issued the "Notice on Further Improving the Safe and Rational Configuration and Use of Innovative Drugs" today (10th). Focusing on the key aspects of the safe and rational deployment and use of innovative drugs, specific policies and measures were proposed in terms of promoting rational deployment, strengthening training and guidance, optimizing use conditions, and improving management measures. First, medical institutions at level 2 and above are required to optimize and improve the admission system and work process of innovative drugs, hold timely meetings of the Pharmacy Management and Therapeutics Committee, and timely include innovative drugs in the institution's drug catalog based on business capabilities and diagnosis and treatment needs. Promote provincial and municipal hospitals to play a leading role step by step. The second is to require regular organization and training of medication knowledge and medical insurance payment policies. Timely compile and publish expert consensus on the clinical use of innovative drugs, and timely incorporate drugs with sufficient evidence-based medicine into clinical diagnosis and treatment guidelines. The third is to implement pharmaceutical-related medical service price items, further improve support and guarantee measures, and optimize the policy environment for the use of innovative drugs. The fourth is to emphasize that there will be no restrictions on the number of total drug varieties and regulations in medical institutions, and it will be clarified that relevant innovative drugs will not be included in the performance monitoring indicators of public medical institutions such as the increase in the average outpatient drug cost and the increase in the average inpatient drug cost.